by Steve Lundeberg, Oregon State University A compound given as a dietary supplement to overweight but otherwise healthy people in a clinical trial caused many of the patients to slim down, research by Oregon State University and Oregon Health & Science University showed. The research, published in the Journal of Nutrition, analyzed the effects of...
In Phase II trial, treatment inhibited key enzyme, resulting in lowered triglyceride production and slower progression of non-alcoholic fatty liver disease to its more dangerous form: non-alcoholic steatohepatitis UNIVERSITY OF CALIFORNIA – SAN DIEGO Using a first-of-its-class drug in a clinical trial, an international research effort headed by a scientist at University of California San...
Cutting out alcohol if you drink in excess can bring about health benefits for your liver, heart, and body composition. The current Dietary Guidelines for Americans recommend that alcohol should be consumed in moderation — up to one drink per day for women and up to two drinks per day for men. Alcohol consumption has...
by Society for Cardiovascular Angiography and Interventions Patients with high lipid levels have an increased risk for ischemic events, despite statin therapy. Findings presented as late-breaking science during the SCAI 2020 Scientific Sessions Virtual Conference revealed that for statin-treated patients with elevated triglycerides and increased cardiovascular risk, icosapent ethyl significantly reduced first and subsequent revascularizations...
by Houston Methodist We’ve all been warned about the dangers of triglycerides, the fat stored in your blood. But what if that unhealthy fat could effectively transport oral medication to your body and eliminate the need for some injections or IV treatment? Houston Methodist nanomedicine researchers are studying this new drug delivery system for a...
